Home/Pipeline/SynKIR™-110

SynKIR™-110

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Verismo Therapeutics

About Verismo Therapeutics

Verismo Therapeutics is developing a next-generation CAR T cell therapy platform, SynKIR™, which utilizes a multi-chain KIR-CAR design to overcome the limitations of traditional single-chain CARs in solid tumors. The platform, invented by founders with deep expertise in cell therapy including the inventors of Kymriah™, has shown promising preclinical efficacy and is now entering early clinical testing. The company's lead programs, SynKIR-110 and SynKIR-310, target solid tumor indications, representing a significant opportunity in a high-unmet-need area of oncology. Verismo is a private, pre-revenue company positioned at the forefront of innovating CAR T cell therapy for solid cancers.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed